Bio-Rad Laboratories, Inc.BIONYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +2.79% | -2.01% | -4.16% | +2.06% | +0.50% |
| Gross Profit Growth | +6.02% | -6.56% | -6.27% | -2.76% | -3.51% |
| EBITDA Growth | +367.05% | -271.62% | -75.78% | +0.00% | -141.67% |
| Operating Income Growth | -29.12% | -40.35% | -54.43% | -24.04% | +1.29% |
| Net Income Growth | +514.71% | -304.69% | -83.33% | +0.00% | -152.34% |
| EPS Growth | +540.27% | -310.45% | -82.99% | +0.00% | -154.34% |
| EPS Diluted Growth | +541.21% | -310.63% | -82.97% | +0.00% | -154.41% |
| Weighted Average Shares Growth | -3.96% | -2.76% | -2.02% | -4.12% | -3.67% |
| Weighted Average Shares Diluted Growth | -4.24% | -2.84% | -2.04% | -4.11% | -3.79% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +67.44% | +53.19% | +86.12% | +19.31% | -26.10% |
| Free Cash Flow Growth | +86.37% | +109.39% | +222.46% | +27.88% | -10.77% |
| Receivables Growth | +0.99% | -7.47% | -4.52% | +5.48% | +2.65% |
| Inventory Growth | +3.67% | -2.63% | +0.86% | -0.61% | -2.62% |
| Asset Growth | -10.86% | -23.86% | -24.45% | +5.43% | -8.55% |
| Book Value per Share Growth | -7.36% | -22.71% | -24.68% | +9.68% | -6.60% |
| Debt Growth | -1.23% | -2.19% | -2.16% | +0.99% | +0.52% |
| R&D Expense Growth | +109.02% | +27.99% | +14.89% | +2.02% | -21.65% |
| SG&A Expenses Growth | -0.38% | -0.92% | -0.80% | +5.91% | +3.17% |